{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:32:41Z","timestamp":1794645161813,"version":"4.9.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ymthe.2025.10.007","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T02:35:08Z","timestamp":1759631708000},"page":"123-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns"],"prefix":"10.1016","volume":"34","author":[{"given":"Dennis J.","family":"Keselman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana C.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Seneviratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"McCague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor L.","family":"Kaschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina W.","family":"Yum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Brandsema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamir","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Loomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Wittlieb-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar H.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy T.","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Samelson-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1556-395X","authenticated-orcid":false,"given":"Susan E.","family":"Matesanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey A.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.10.007_bib1","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.10.007_bib2","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current Clinical Applications of AAV-mediated Gene Therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.10.007_bib3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/21678707.2015.1088780","article-title":"Gene Therapy for Duchenne muscular dystrophy","volume":"3","author":"Ramos","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymthe.2025.10.007_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"Mendell","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2025.10.007_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.10.007_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8+ T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.10.007_bib9","series-title":"Presented at the World Muscle Society 2024 Annual Congress, Prague, Czechia","article-title":"Long-term safety and tolerability of delandistrogene moxeparvovec in Duchenne muscular dystrophy: phase 1 to phase 3 clinical trials","author":"Proud","year":"2024"},{"key":"10.1016\/j.ymthe.2025.10.007_bib10","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.10.007_bib11","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.10.007_bib12","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.10.007_bib13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.10.007_bib14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.10.007_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience","volume":"8","author":"Friese","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.10.007_bib16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.10.007_bib17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.21037\/qims-23-790","article-title":"Association of increased epicardial adipose tissue derived from cardiac magnetic resonance imaging with myocardial fibrosis in Duchenne muscular dystrophy: a clinical prediction model development and validation study in 283 participants","volume":"14","author":"Yuan","year":"2024","journal-title":"Quant. Imaging Med. Surg."},{"key":"10.1016\/j.ymthe.2025.10.007_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1532-429X-15-107","article-title":"Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function","volume":"15","author":"Hor","year":"2013","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.ymthe.2025.10.007_bib19","series-title":"Presented at the Academy of Managed Care Pharmacy (AMCP) 2025 Congress, Houston, TX","article-title":"Cardiac MRI Outcomes in Patients with Duchenne Muscular Dystrophy Treated with Delandistrogene Moxeparvovec: Findings from EMBARK Part 1 [Abstract]","author":"Walter","year":"2025"},{"key":"10.1016\/j.ymthe.2025.10.007_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165869","article-title":"Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy","volume":"9","author":"Hart","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.10.007_bib21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jacbts.2024.12.015","article-title":"Long-Term Dystrophin Replacement Therapy in Duchenne Muscular Dystrophy Causes Cardiac Inflammation","volume":"10","author":"Forand","year":"2025","journal-title":"JACC. Basic Transl. Sci."},{"key":"10.1016\/j.ymthe.2025.10.007_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/22143602241303357","article-title":"Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance","volume":"12","author":"Kaufman","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.10.007_bib23","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0883073810371004","article-title":"Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management","volume":"25","author":"Moxley","year":"2010","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ymthe.2025.10.007_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221097","article-title":"Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy","volume":"14","author":"Muntoni","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.10.007_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105281","article-title":"Motor Function Testing Rates and Outcomes in Duchenne Muscular Dystrophy with Comorbid Autism and Attention-Deficit\/Hyperactivity Disorder","volume":"48","author":"Keselman","year":"2025","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.10.007_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1\/2a nonrandomized trial","volume":"69","author":"Mendell","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.10.007_bib27","series-title":"Presented at the Muscular Dystrophy Association 2025 Annual Conference, Dallas, TX","article-title":"Long-Term Functional Outcomes, Safety, and Micro-dystrophin Expression Following Delandistrogene Moxeparvovec Treatment in DMD: EMBARK 2-Year Results","author":"Mendell","year":"2025"},{"key":"10.1016\/j.ymthe.2025.10.007_bib28","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1016\/j.ymthe.2025.08.029","article-title":"The future of gene therapy: Safer vectors, sharper focus: High-profile failures demand deep root cause analysis \u2014 but the transformative potential of AAV remains within reach if the field is willing to learn and evolve","volume":"33","author":"Chamberlain","year":"2025","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625008287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625008287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:30:25Z","timestamp":1783020625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625008287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1525001625008287"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.10.007","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}